Form 4: Blueprint Medicines Officer Sells Shares Under 10b5-1 Trading Plan

L. Becker Hewes, Chief Medical Officer of Blueprint Medicines, sold 2,424 shares of common stock at $104.91 per share on June 4, 2024, under a pre-arranged trading plan.

Summary

• On June 4, 2024, L. Becker Hewes, the Chief Medical Officer of Blueprint Medicines Corp, sold 2,424 shares of common stock.
• The sale was executed at a price of $104.91 per share.
• The transaction was conducted under a pre-arranged trading plan adopted on March 1, 2024, in accordance with Rule 10b5-1.
• Following the transaction, Hewes directly owns 29,514 shares of Blueprint Medicines Corp.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports a routine stock sale under a pre-existing trading plan. There is no indication of positive or negative implications for the company.

Industry Context

Insider sales are a common occurrence in publicly traded companies and are often scrutinized by investors. Sales executed under a 10b5-1 trading plan are generally viewed as less impactful since they are pre-arranged and not based on current insider information.

Stakeholder Impact

• The stock sale may have a minor impact on shareholders, but is unlikely to be significant given the relatively small number of shares sold and the existence of a pre-arranged trading plan.

Key Dates